MLYS News and Press, Mineralys Therapeutics Inc.

2026-04-07 11:30:05 ET Jon Congleton, Chief Executive Officer of Mineralys Therapeutics (NASDAQ:MLYS) , reported the sale of 75,000 shares in multiple open-market transactions on March 31 valued at approximately $1.97 million, according to an SEC Form 4 filing . Transactio...

RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven b...

2026-03-13 16:03:14 ET Dennis Ding from Jefferies issued a price target of $30.00 for MLYS on 2026-03-13 16:40:00. The adjusted price target was set to $30.00. At the time of the announcement, MLYS was trading at $26.23. The overall price target consensus is at $54.00 wi...

2026-03-13 12:05:48 ET Investment Overview Mineralys Therapeutics, Inc. ( MLYS ), the Radnor Pennsylvania based biotech focused on the development of lorundrostat - an orally administered aldosterone synthase inhibitor ("ASI") indicated for the treatment of cardiorenal condition...

2026-03-12 19:33:00 ET More on Mineralys Therapeutics Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 Mineralys spikes as blood pressure drug undergoes FDA review Seeking Alpha...

2026-03-12 19:32:17 ET Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call March 12, 2026 4:30 PM EDT... Read the full article on Seeking Alpha For further details see: Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript

2026-03-12 18:02:49 ET Image source: The Motley Fool. Thursday, March 12, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-03-12 16:36:14 ET More on Mineralys Therapeutics Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 Mineralys spikes as blood pressure drug undergoes FDA review Seeking Alpha’s Quant Rating on Mineralys Therapeutics Historical earnings data...

–  Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, In...

EHang Holdings Limited (EH) is expected to report $-0.06 for Q4 2025 McEwen Inc. (MUX) is expected to report $0.25 for Q4 2025 Hannover Ruck SE ADR - Level I (HVRRY) is expected to report $1.03 for Q4 2025 VAALCO Energy Inc. (EGY) is expected to report $0.02 for Q4 2025 Full Truck...